Alex Nemiroff

Antisense oligonucleotide therapy for SCN2A gain-of-function epilepsy

C. Reid, S. Petrou, F. Rigo, 2020, bioRxiv.

Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy model.

C. Reid, S. Petrou, F. Rigo, 2021, The Journal of clinical investigation.

Distinctive In Vitro Phenotypes in iPSC-Derived Neurons From Patients With Gain- and Loss-of-Function SCN2A Developmental and Epileptic Encephalopathy

C. Reid, S. Petrou, S. Maljevic, 2023, The Journal of Neuroscience.

Variant-specific in vitro neuronal network phenotypes and drug sensitivity in SCN2A developmental and epileptic encephalopathy.

Melody Li, A. Sedo, L. Burbano, 2024, Journal of neurochemistry.